Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention

被引：31

作者：

Galli, Mattia ^{[1
,2
]}

Laborante, Renzo ^{[1
]}

Andreotti, Felicita ^{[1
,3
]}

Vergallo, Rocco ^{[3
]}

Montone, Rocco Antonio ^{[3
]}

Iaconelli, Antonio ^{[3
]}

Trani, Carlo ^{[1
,3
]}

Burzotta, Francesco ^{[1
,3
]}

Crea, Filippo ^{[1
,3
]}

D'Amario, Domenico ^{[3
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dept Cardiovasc & Pulm Sci, I-00168 Rome, Italy

[2] GVM Care & Res, Maria Cecilia Hosp, Dept Cardiol, I-48033 Cotignola, Italy

[3] Fdn Policlin Univ A Gemelli, Dept Cardiovasc Med, IRCCS, I-00168 Rome, Italy

来源：

REVIEWS IN CARDIOVASCULAR MEDICINE | 2022年 / 23卷 / 08期

关键词：

percutaneous coronary interventions; bleeding; complications; antithrombotic therapy; ST-SEGMENT-ELEVATION; DRUG-ELUTING STENTS; ACUTE MYOCARDIAL-INFARCTION; DUAL ANTIPLATELET THERAPY; ARTERY-DISEASE; RISK STRATIFICATION; ATRIAL-FIBRILLATION; P2Y(12) INHIBITORS; CLINICAL-OUTCOMES; ELDERLY-PATIENTS;

D O I：

10.31083/j.rcm2308286

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Percutaneous coronary intervention (PCI) is considered a relatively safe procedure associated with low rates of complications, but is inevitably associated with short and mid-to-long term increased bleeding risk. Besides the short term risk associated with the arterial access to perform PCI, enhanced bleeding risk persists for several months, given the need for antithrombotic therapy to prevent procedurerelated thrombotic complications as well as ischemic recurrences. Bleeding is a powerful harbinger of adverse outcomes. This awareness has fuelled intense research on bleeding reduction strategies, including new PCI devices and techniques as well as new medications and antithrombotic regimens. We here review the mechanisms and prevalence of bleeding in PCI patients, discuss the available evidence from a practical point of view, and explore future perspectives on how to treat and prevent bleeding complications in these patients.

引用

页数：23

共 108 条

[1] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Ageno, Walter ;

Gallus, Alexander S. ;

Wittkowsky, Ann ;

Crowther, Mark ;

Hylek, Elaine M. ;

Palareti, Gualtiero .

CHEST, 2012, 141 (02) :E44S-E88S

[2] Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 2: Treatment [J].

Ageno, Walter ;

Garcia, David ;

Aguilar, Maria I. ;

Douketis, James ;

Finazzi, Guido ;

Imberti, Davide ;

Iorio, Alfonso ;

Key, Nigel S. ;

Lim, Wendy ;

Marietta, Marco ;

Prisco, Domenico ;

Sarode, Ravi ;

Testa, Sophie ;

Tosetto, Alberto ;

Crowther, Mark .

AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (09) :584-588

[3] Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial [J].

Anderson, J. A. M. ;

Hirsh, J. ;

Yusuf, S. ;

Johnston, M. ;

Afzal, R. ;

Mehta, S. R. ;

Fox, K. A. A. ;

Budaj, A. ;

Eikelboom, J. W. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) :243-249

[4] Antiplatelet therapy after percutaneous coronary intervention [J].

Angiolillo, Dominick J. ;

Galli, Mattia ;

Collet, Jean-Philippe ;

Kastrati, Adnan ;

O'Donoghue, Michelle L. .

EUROINTERVENTION, 2022, 17 (17) :E1371-E1396

[5] Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel The ABCD-GENE Score [J].

Angiolillo, Dominick J. ;

Capodanno, Davide ;

Danchin, Nicolas ;

Simon, Tabassome ;

Bergmeijer, Thomas O. ;

ten Berg, Jurrien M. ;

Sibbing, Dirk ;

Price, Matthew J. .

JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (05) :606-617

[6] Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study [J].

Angiolillo, Dominick J. ;

Bhatt, Deepak L. ;

Lanza, Frank ;

Cryer, Byron ;

Dong, Jin-fei ;

Jeske, Walter ;

Zimmerman, Ronald R. ;

von Chong, Estela ;

Prats, Jayne ;

Deliargyris, Efthymios N. ;

Marathi, Upendra .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (04) :554-562

[7] Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects [J].

Ansell, Jack ;

Bakhru, Sasha ;

Laulicht, Bryan E. ;

Tracey, Gregory ;

Villano, Stephen ;

Freedman, Daniel .

EUROPEAN HEART JOURNAL, 2022, 43 (10) :985-992

[8] Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants [J].

Ansell, Jack ;

Laulicht, Bryan E. ;

Bakhru, Sasha H. ;

Burnett, Allison ;

Jiang, Xuan ;

Chen, Lirong ;

Baker, Christopher ;

Villano, Stephen ;

Steiner, Solomon .

BLOOD, 2021, 137 (01) :115-125

[9] Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention [J].

Aradi, Daniel ;

Kirtane, Ajay ;

Bonello, Laurent ;

Gurbel, Paul A. ;

Tantry, Udaya S. ;

Huber, Kurt ;

Freynhofer, Matthias K. ;

ten Berg, Jurrien ;

Janssen, Paul ;

Angiolillo, Dominick J. ;

Siller-Matula, Jolanta M. ;

Marcucci, Rossella ;

Patti, Giuseppe ;

Mangiacapra, Fabio ;

Valgimigli, Marco ;

Morel, Olivier ;

Palmerini, Tullio ;

Price, Matthew J. ;

Cuisset, Thomas ;

Kastrati, Adnan ;

Stone, GreggW. ;

Sibbing, Dirk .

EUROPEAN HEART JOURNAL, 2015, 36 (27) :1762-1771

[10]

Bhatt DL, 2021, NEJM EVIDENCE, V1

← 1 2 3 4 5 6 7 8 9 10 →